Samir Parekh

10.0k total citations
179 papers, 2.8k citations indexed

About

Samir Parekh is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Samir Parekh has authored 179 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Hematology, 85 papers in Molecular Biology and 79 papers in Oncology. Recurrent topics in Samir Parekh's work include Multiple Myeloma Research and Treatments (96 papers), Protein Degradation and Inhibitors (46 papers) and CAR-T cell therapy research (39 papers). Samir Parekh is often cited by papers focused on Multiple Myeloma Research and Treatments (96 papers), Protein Degradation and Inhibitors (46 papers) and CAR-T cell therapy research (39 papers). Samir Parekh collaborates with scholars based in United States, United Kingdom and Canada. Samir Parekh's co-authors include Sundar Jagannath, Hearn Jay Cho, Violetta V. Leshchenko, Ajai Chari, Deepu Madduri, Alessandro Laganà, Joshua Richter, Shambavi Richard, Joshua Brody and Oliver Van Oekelen and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Samir Parekh

166 papers receiving 2.8k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Samir Parekh	1.3k	1.3k	892	512	407	179	2.8k
Walter E. Aulitzky	1.1k 0.8×	1.4k 1.1×	1.1k 1.2×	502 1.0×	420 1.0×	121	3.6k
Bhagirathbhai Dholaria	1.6k 1.3×	718 0.6×	754 0.8×	728 1.4×	164 0.4×	139	2.5k
Michael Rytting	1.3k 1.1×	1.1k 0.9×	2.1k 2.3×	312 0.6×	414 1.0×	96	4.2k
Hetty E. Carraway	1.1k 0.8×	1.7k 1.4×	1.4k 1.6×	488 1.0×	265 0.7×	212	3.6k
Stefan Nagel	721 0.6×	1.3k 1.1×	592 0.7×	655 1.3×	420 1.0×	125	2.9k
Leo Rasche	1.3k 1.0×	1.1k 0.8×	1.3k 1.4×	394 0.8×	233 0.6×	140	2.3k
Mark Roschewski	1.3k 1.1×	779 0.6×	485 0.5×	420 0.8×	1.4k 3.5×	131	2.9k
Valérie Gouilleux‐Gruart	1.4k 1.1×	1.0k 0.8×	556 0.6×	1.2k 2.3×	338 0.8×	82	3.0k
Brian T. Hill	1.2k 0.9×	746 0.6×	482 0.5×	475 0.9×	962 2.4×	225	2.7k
Geoffrey L. Uy	1.5k 1.2×	1.6k 1.3×	2.9k 3.3×	900 1.8×	292 0.7×	214	4.6k

Countries citing papers authored by Samir Parekh

Since Specialization

Citations

This map shows the geographic impact of Samir Parekh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samir Parekh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samir Parekh more than expected).

Fields of papers citing papers by Samir Parekh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samir Parekh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samir Parekh. The network helps show where Samir Parekh may publish in the future.

Co-authorship network of co-authors of Samir Parekh

This figure shows the co-authorship network connecting the top 25 collaborators of Samir Parekh. A scholar is included among the top collaborators of Samir Parekh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samir Parekh. Samir Parekh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gleason, Charles, John F. Crary, Lusheng Song, et al.. (2025). Progressive multifocal leukoencephalopathy and BK virus-nephropathy with bispecific antibody therapy in multiple myeloma. Haematologica. 111(1). 431–435. 1 indexed citations

Aleman, Adolfo, Erin Moshier, Adriana Rossi, et al.. (2025). Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy. Clinical Cancer Research. 31(20). 4333–4344. 1 indexed citations

Tordjman, Mickaël, Murat Yüce, Giuseppe Petralia, et al.. (2025). Comparison of MRI, [18F]FDG-PET/CT, and [18F]FDG-PET/MRI for Initial Staging of Multiple Myeloma. Clinical Nuclear Medicine. 50(11). 1006–1015.

Lee, Heng‐Huan, Ravi Prakash Shukla, Violetta V. Leshchenko, et al.. (2024). Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance. Blood. 144(Supplement 1). 1402–1402. 1 indexed citations

Coffey, David G., Keren Osman, Adolfo Aleman, et al.. (2024). Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma. Journal for ImmunoTherapy of Cancer. 12(4). e008110–e008110. 5 indexed citations

Chen, Lucia, Santiago Thibaud, Ajai Chari, et al.. (2023). Durable MRD and Imaging-Negative Remission ≥ 5 Years Post-Therapy Predicts Long-Term Progression-Free Survival in Multiple Myeloma Patients - a Single-Center Observational Study. Blood. 142(Supplement 1). 1998–1998.

Lancman, Guido, Lisa Avery, Hearn Jay Cho, et al.. (2023). IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood Cancer Discovery. 4(6). 440–451. 56 indexed citations

Upadhyay, Ranjan, Jonathan Boiarsky, Judit Svensson‐Arvelund, et al.. (2021). A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy. Cancer Discovery. 11(3). 599–613. 125 indexed citations

Sindhu, Kunal K., Erin Moshier, Joshua Richter, et al.. (2021). The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 22(3). 192–197. 6 indexed citations

10.

Lancman, Guido, Samantha E. Jacobs, John T. Doucette, et al.. (2021). Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 21(5). e470–e476. 18 indexed citations

11.

Oekelen, Oliver Van, Adolfo Aleman, Bhaskar Upadhyaya, et al.. (2021). Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nature Medicine. 27(12). 2099–2103. 151 indexed citations

12.

Leng, Siyang, Erin Moshier, Douglas Tremblay, et al.. (2020). Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies. Clinical Lymphoma Myeloma & Leukemia. 20(10). e734–e751. 2 indexed citations

13.

Pierceall, William E., Michael Amatangelo, Nizar J. Bahlis, et al.. (2020). Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research. 26(22). 5895–5902. 27 indexed citations

14.

Perumal, Deepak, Naoko Imai, Alessandro Laganà, et al.. (2019). Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. Clinical Cancer Research. 26(2). 450–464. 59 indexed citations

15.

Perumal, Deepak, Violetta V. Leshchenko, Zewei Jiang, et al.. (2016). Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. Cancer Research. 76(5). 1225–1236. 27 indexed citations

16.

Yu, Jingwei, Boris Bartholdy, Zijun Y. Xu‐Monette, et al.. (2016). An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL. Blood. 128(24). 2797–2807. 48 indexed citations

17.

Leshchenko, Violetta V., et al.. (2013). Integrative Genomic Analysis of Temozolomide Resistance in Diffuse Large B-Cell Lymphoma. Clinical Cancer Research. 20(2). 382–392. 17 indexed citations

18.

Petrich, Adam M., Violetta V. Leshchenko, Bing Xia, et al.. (2012). Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma. Clinical Cancer Research. 18(9). 2534–2544. 48 indexed citations

19.

Will, Britta, Masahiro Kawahara, Ingmar Bruns, et al.. (2009). Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood. 114(18). 3899–3908. 95 indexed citations

20.

Parekh, Samir, José M. Polo, Rita Shaknovich, et al.. (2007). BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood. 110(6). 2067–2074. 105 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact